VETOQUINOL SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97 EUR | -4.90% |
|
-5.09% | -5.27% |
| Apr. 30 | Vetoquinol: down after sales update | CF |
| Apr. 29 | Vetoquinol SA Reports Sales Results for the First Quarter of Fiscal 2024 | CI |
| Sales 2024 * | 551M 590M | Sales 2025 * | 577M 618M | Capitalization | 1.15B 1.23B |
|---|---|---|---|---|---|
| Net income 2024 * | 56M 59.93M | Net income 2025 * | 61M 65.28M | EV / Sales 2024 * | 1.75 x |
| Net cash position 2024 * | 183M 196M | Net cash position 2025 * | 235M 251M | EV / Sales 2025 * | 1.58 x |
| P/E ratio 2024 * |
20.3
x | P/E ratio 2025 * |
18.7
x | Employees | 2,440 |
| Yield 2024 * |
0.8% | Yield 2025 * |
0.86% | Free-Float | 32.57% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -4.90% | ||
| 1 week | -5.09% | ||
| Current month | -4.90% | ||
| 1 month | -3.00% | ||
| 3 months | -6.37% | ||
| 6 months | +4.86% | ||
| Current year | -5.27% |
1 week
96.20
104.00
1 month
96.20106.00
Current year
92.60110.00
1 year
76.30110.00
3 years
76.30161.00
5 years
41.90161.00
10 years
32.10161.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 01-04-01 | |
| Director of Finance/CFO | 59 | - | |
Philippe Gruet
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Étienne Frechin
BRD | Director/Board Member | 86 | 62-07-01 |
| Chief Executive Officer | 55 | 01-04-01 | |
Philippe Arnold
BRD | Director/Board Member | 83 | 07-06-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +3.87% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 97 | -4.90% | 5,453 |
| 24-06-13 | 102 | 0.00% | 3,369 |
| 24-06-12 | 102 | -0.58% | 1,662 |
| 24-06-11 | 102.6 | +0.20% | 2,441 |
| 24-06-10 | 102.4 | +0.20% | 4,340 |
Real-time Euronext Paris, June 14, 2024 at 11:35 am EDT
More quotes
Vetoquinol SA specializes in the research, development, production and marketing of veterinary drugs and products for pets (67.7% of net sales; dogs, cats, etc.) and livestock (32.3%; cattle, pigs, poultry, etc.). The group's activity is organized around 4 product families:
- antibiotics;
- anti-inflammatories;
- cardiology and nephrology treatments;
- other: anti-parasitics, vaccines, and nutritional products.
At the end of 2022, the group had 5 production sites throughout the world.
Net sales are distributed geographically as follows: Europe (46.7%), the Americas (36%) and Asia/Pacific (17.3%).
Sector
Pharmaceuticals
Calendar
2024-09-11
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
97
EUR
Average target price
105.8
EUR
Spread / Average Target
+9.11%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.27% | 1.23B | |
| +21.01% | 8.91B | |
| +21.62% | 3.6B | |
| -5.56% | 3.04B | |
| +13.68% | 1.67B | |
| -29.81% | 1.16B | |
| -31.11% | 1.15B | |
| -22.47% | 1.01B | |
| -12.32% | 916M | |
| -3.22% | 889M |
- Stock Market
- Equities
- VETO Stock
